Amgen Inc. (NASDAQ: AMGN) was trading at approximately $330.61 to $331.70 on Friday, May 22, within a session range of $328.00 to $332.33 in volume broadly in line with recent daily averages.
The stock’s 52-week range of $261.43 to $391.29 reflects a year of volatile performance, with AMGN having surged to an all-time closing high of $385.25 in late February before retreating through the spring months.
The most significant news for Amgen on Friday was a report citing the Wall Street Journal that at least 20 people in Japan who took Amgen’s rare disease drug have died, while 22 others developed potentially fatal liver injuries.
Kissei Pharmaceutical, which sells the affected drug in Japan, moved to warn doctors to stop prescribing it to new patients following the safety alert.
The report raised fresh questions about the regulatory and reputational implications for Amgen’s pipeline, even as the company insisted its core US business remains robust.
Amgen had also been in the news earlier in the week after announcing the retirement of CFO Peter Griffith and the appointment of Thomas Dittrich as his successor, a transition that had been anticipated by analysts.
The company’s Q1 2026 results, reported earlier in May, showed strong growth driven by Repatha, its cholesterol-lowering antibody, and UPLIZNA, a treatment for neuromyelitis optica.
Amgen announced plans earlier this month to invest in US manufacturing capacity, which the company framed as strengthening American supply chain resilience for biologic drug production.
The consensus analyst view on AMGN is broadly a hold, with the average 12-month price target around $332 to $357 depending on the firm, reflecting limited upside at current levels.
The Japan drug safety story will be monitored closely in the coming weeks as regulators assess whether action beyond the initial doctor warning is required.
